Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure – narrative review of the literature – case report

Necrotizing autoimmune myopathy is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation. We describe a 58-year-old woman with previous breast cancer and statin use who complained of rapidly progressive weakness of lower limbs without pain, making walking, running and climbing stairs difficult. The creatine kinase level was 2,843 U/L, and muscle biopsy showed a dystrophic pattern. The genetic test for muscular dystrophies was negative and for anti-3-hydroxy-3-methylglutaryl coenzyme A reductase was positive. Intravenous immunoglobulin was administered, which showed mild improvement. Unfortunately, she took a step and collapsed to the floor, which led to the fracture of right femur delaying her improvement. The diagnosis of necrotizing autoimmune myopathy is sometimes delayed due to the atypical pathologic findings on muscle biopsy. As the disease is a severe condition, prompt recognition can lead to a successful outcome. We advise to consider this entity as a differential diagnosis among muscular dystrophies.

[1]  A. Mammen,et al.  Anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme a reductase necrotizing myopathy masquerading as a muscular dystrophy in a child , 2017, Muscle & nerve.

[2]  P. Vermersch,et al.  Anti-HMGCR Antibody–Related Necrotizing Autoimmune Myopathy Mimicking Muscular Dystrophy , 2017, Neuropediatrics.

[3]  Tasneam Shagroni,et al.  Statin-associated autoimmune myopathy. , 2017, Rheumatology.

[4]  O. Landon-Cardinal Anti-HMGCR Necrotizing Autoimmune Myopathy Leading to Identification of Cancer Relapse , 2017 .

[5]  I. Nishino,et al.  Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies , 2016, Rheumatology.

[6]  A. Hida,et al.  Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[7]  V. Jooste,et al.  High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. , 2016, Brain : a journal of neurology.

[8]  A. Mammen Necrotizing myopathies: beyond statins , 2014, Current opinion in rheumatology.

[9]  L. Servais,et al.  Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies , 2014, Medicine.

[10]  Richard G. Fowler,et al.  Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies , 2014, Journal of immunology research.

[11]  Y. Allenbach,et al.  [Acquired necrotizing myopathies]. , 2013, La Revue de medecine interne.

[12]  Y. Hayashi,et al.  Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. , 2012, Archives of neurology.

[13]  A. Mammen,et al.  Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. , 2011, Arthritis and rheumatism.

[14]  I. Targoff,et al.  Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies: Analysis of 100 French Canadian Patients , 2005, Medicine.

[15]  R. Hughes,et al.  119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[16]  T. Kumamoto [Necrotizing myopathies]. , 2001, Ryoikibetsu shokogun shirizu.